It has been about a month since the last earnings report for Immunovant, Inc. (IMVT) . Shares have added about 13.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Immunovant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Immunovant's Q1 Earnings Miss Estimates ...

Part I [Business](index=10&type=section&id=Item%201.%20Business) Immunovant is a clinical-stage immunology company developing anti-FcRn antibodies, IMVT-1402 and batoclimab, for autoimmune diseases - The company's core strategy is to develop its lead asset, **IMVT-1402**, for a wide range of autoimmune diseases, leveraging its potential best-in-class profile of **potent IgG reduction** without the associated negative effects on albumin and LDL cholesterol seen in other FcRn inhibitors[27](index=27&type=chunk)[31](index=31&type=chunk)[35](index=35&type=chunk) Development Pipeline | Investigational Compound | Therapeutic Area | Target Indication | Stage of Development | | :--- | :--- | :--- | :--- | | **IMVT-1402** | Autoimmune Diseases | | Phase 1 | | **Batoclimab** | Neurological Diseases | Myasthenia Gravis (MG) | Pivotal Trial (Phase 3) | | | | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Pivotal Trial (Phase 2b) | | | Endocrine Diseases | Thyroid Eye Disease (TED) | Pivotal Trials (Phase 3) | | | | Graves' Disease (GD) | Proof of Concept Study (Phase 2) | - IMVT-1402 demonstrated a statistically significant **74% reduction in mean total IgG levels** after four weekly 600 mg subcutaneous doses in a Phase 1 trial, with no or minimal impact on albumin and LDL cholesterol levels, similar to placebo[56](index=56&type=chunk) - The company plans an aggressive development timeline for IMVT-1402, aiming to initiate **4-5 potentially registrational programs by March 31, 2025**, and a total of **ten indications by March 31, 2026**[35](index=35&type=chunk)[61](index=61&type=chunk) - Under the license agreement with HanAll Biopharma, Immunovant is obligated to pay up to an aggregate of **$420.0 million** in future regulatory and sales milestones, in addition to tiered royalties on net sales[107](index=107&type=chunk) - The company faces **significant competition** from other FcRn inhibitors, including approved products like VYVGART® (efgartigimod) from argenx and RYSTIGGO® (rozanolixizumab) from UCB, as well as candidates in development from Johnson & Johnson and Viridian Therapeutics[120](index=120&type=chunk)[268](index=268&type=chunk) [Risk Factors](index=52&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks related to product development, regulatory approval, competition, financial sustainability, and third-party reliance - The business is entirely dependent on the **successful and timely development, regulatory approval, and commercialization** of its product candidates, IMVT-1402 and batoclimab[235](index=235&type=chunk) - Adverse events are a significant risk. Batoclimab clinical trials were previously paused due to **treatment-induced elevations in total cholesterol and LDL levels**, which could impact long-term risk-benefit assessment and regulatory approval[239](index=239&type=chunk)[241](index=241&type=chunk) - The company faces **intense competition** from other FcRn inhibitors, including FDA-approved VYVGART® Hytrulo and RYSTIGGO®, and candidates in development from major pharmaceutical companies like Johnson & Johnson[268](index=268&type=chunk) - As of May 22, 2024, Roivant Sciences Ltd. (RSL) beneficially owned approximately **54.6% of the company's voting power**, making Immunovant a "controlled company" and giving RSL significant influence over matters subject to stockholder approval[457](index=457&type=chunk) - The company has a limited operating history, has never generated product revenue, and expects to incur significant losses for the foreseeable future. As of March 31, 2024, the accumulated deficit was **$825.7 million**[324](index=324&type=chunk)[327](index=327&type=chunk) - The company relies on a license agreement with HanAll Biopharma for the core intellectual property of IMVT-1402 and batoclimab. **Termination of this agreement would severely impact the business**[340](index=340&type=chunk) [Unresolved Staff Comments](index=106&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports that it has no unresolved staff comments from the SEC - There are **no unresolved staff comments**[486](index=486&type=chunk) [Cybersecurity](index=106&type=section&id=Item%201C.%20Cybersecurity) The company has established processes to manage cybersecurity risks, integrated into its overall enterprise risk management - The company's cybersecurity risk management is integrated into its overall enterprise risk management process, focusing on **data protection, access control, and incident response**[487](index=487&type=chunk) - Oversight is provided by the Audit Committee of the Board of Directors, which receives management updates on cybersecurity matters **at least twice annually**[492](index=492&type=chunk) - Operational leadership for cybersecurity is provided by the VP of Information Technology and Facilities and the Head of Cybersecurity, who possess over **16 and 15 years of relevant experience**, respectively[493](index=493&type=chunk) [Properties](index=108&type=section&id=Item%202.%20Properties) The company conducts its business operations from leased office spaces in New York, NY, and Durham, NC, with international subsidiary offices - The company's primary U.S. operations are located at **320 West 37th Street, New York, NY** and **1000 Park Forty Plaza, Durham, NC**[495](index=495&type=chunk) - International subsidiary offices are located in **Hamilton, Bermuda; London, UK; and Basel, Switzerland**[495](index=495&type=chunk) [Legal Proceedings](index=108&type=section&id=Item%203.%20Legal%20Proceedings) A securities class action complaint filed in February 2021 was dismissed with prejudice in March 2024, concluding the litigation - A putative securities class action complaint filed against the company in February 2021 was **dismissed with prejudice on March 29, 2024**. The litigation is now concluded as the plaintiffs did not appeal the judgment[698](index=698&type=chunk) [Mine Safety Disclosures](index=108&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[499](index=499&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=109&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on The Nasdaq Global Select Market, and it has never paid cash dividends - The company's common stock is listed on **The Nasdaq Global Select Market** under the ticker symbol **"IMVT"**[502](index=502&type=chunk) - The company has **never declared or paid dividends** and does not plan to in the foreseeable future, retaining all future earnings for business operations[504](index=504&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=110&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company reported an increased net loss for FY2024, driven by higher R&D and G&A expenses, with its cash position significantly strengthened by a recent equity offering Results of Operations | | Years Ended March 31, | Change | | :--- | :--- | :--- | :--- | | | **2024 (in thousands)** | **2023 (in thousands)** | **$ (in thousands)** | | Research and development | $212,928 | $160,257 | $52,671 | | Acquired in-process R&D | $12,500 | $10,000 | $2,500 | | General and administrative | $57,281 | $48,019 | $9,262 | | **Net loss** | **$(259,336)** | **$(210,960)** | **$(48,376)** | - The increase in R&D expenses was primarily driven by a **$32.8 million** rise in costs for the IMVT-1402 program and a **$25.2 million** increase in unallocated personnel-related expenses due to higher headcount[547](index=547&type=chunk)[548](index=548&type=chunk) - The company's cash and cash equivalents increased to **$635.4 million** as of March 31, 2024, from **$376.5 million** a year prior, mainly due to net proceeds of **$466.7 million** from an underwritten public offering and concurrent private placement in October 2023[552](index=552&type=chunk)[555](index=555&type=chunk) - Management expects that existing cash and cash equivalents are sufficient to fund operating expenses and capital expenditure requirements for **at least the next 12 months** from the filing date[572](index=572&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=120&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is not required to provide this information as it qualifies as a "smaller reporting company" - The company is **exempt from this disclosure requirement** because it is a "smaller reporting company"[579](index=579&type=chunk) [Financial Statements and Supplementary Data](index=121&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) The audited financial statements for FY2024 show an increased net loss, a substantial accumulated deficit, and a significant rise in stockholders' equity due to recent equity financing Consolidated Balance Sheet Data | | March 31, 2024 (in thousands) | March 31, 2023 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $635,365 | $376,532 | | Total assets | $666,365 | $405,838 | | Total liabilities | $48,608 | $43,344 | | Accumulated deficit | $(825,683) | $(566,347) | | Total stockholders' equity | $617,757 | $362,494 | Consolidated Statement of Operations Data | | Year Ended March 31, 2024 (in thousands) | Year Ended March 31, 2023 (in thousands) | | :--- | :--- | :--- | | Research and development | $212,928 | $160,257 | | General and administrative | $57,281 | $48,019 | | **Net loss** | **$(259,336)** | **$(210,960)** | | **Net loss per share** | **$(1.88)** | **$(1.71)** | - The company achieved development and regulatory milestones under the HanAll Agreement, resulting in acquired IPR&D expenses of **$12.5 million** in fiscal 2024 and **$10.0 million** in fiscal 2023[651](index=651&type=chunk) - As of March 31, 2024, the company has a remaining minimum purchase commitment of approximately **$46.2 million** under its manufacturing agreement with Samsung Biologics[654](index=654&type=chunk)[699](index=699&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=146&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - **None reported**[702](index=702&type=chunk) [Controls and Procedures](index=146&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective as of March 31, 2024 - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were **effective as of March 31, 2024**[705](index=705&type=chunk) - Management concluded that the company's internal control over financial reporting was **effective as of March 31, 2024**, based on the COSO 2013 framework[709](index=709&type=chunk) - The independent registered public accounting firm, Ernst & Young LLP, issued an **unqualified opinion on the effectiveness of the company's internal control over financial reporting as of March 31, 2024**[710](index=710&type=chunk)[714](index=714&type=chunk) [Other Information](index=149&type=section&id=Item%209B.%20Other%20Information) No directors or Section 16 reporting officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement during the fourth quarter - **No directors or Section 16 officers adopted, modified, or terminated a Rule 10b5-1 trading plan during the fourth quarter**[721](index=721&type=chunk) [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](index=149&type=section&id=Item%209C.%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections) This item is not applicable to the company - Not applicable[722](index=722&type=chunk) Part III [Directors, Executive Officers and Corporate Governance](index=150&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information for this item will be provided in the company's 2024 Proxy Statement and is incorporated by reference - Information for this item is **incorporated by reference** from the registrant's definitive Proxy Statement for its 2024 Annual Meeting of Stockholders[724](index=724&type=chunk)[725](index=725&type=chunk) [Executive Compensation](index=150&type=section&id=Item%2011.%20Executive%20Compensation) Information for this item will be provided in the company's 2024 Proxy Statement and is incorporated by reference - Information for this item is **incorporated by reference** from the registrant's definitive Proxy Statement for its 2024 Annual Meeting of Stockholders[724](index=724&type=chunk)[727](index=727&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=150&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information for this item will be provided in the company's 2024 Proxy Statement and is incorporated by reference - Information for this item is **incorporated by reference** from the registrant's definitive Proxy Statement for its 2024 Annual Meeting of Stockholders[724](index=724&type=chunk)[728](index=728&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=150&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information for this item will be provided in the company's 2024 Proxy Statement and is incorporated by reference - Information for this item is **incorporated by reference** from the registrant's definitive Proxy Statement for its 2024 Annual Meeting of Stockholders[724](index=724&type=chunk)[729](index=729&type=chunk) [Principal Accountant Fees and Services](index=150&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information for this item will be provided in the company's 2024 Proxy Statement and is incorporated by reference - Information for this item is **incorporated by reference** from the registrant's definitive Proxy Statement for its 2024 Annual Meeting of Stockholders[724](index=724&type=chunk)[730](index=730&type=chunk) Part IV [Exhibit and Financial Statement Schedules](index=151&type=section&id=Item%2015.%20Exhibit%20and%20Financial%20Statement%20Schedules) This section lists the documents filed as part of the Annual Report, including financial statements and a comprehensive list of exhibits - All required financial statements are included in **Part II, Item 8** of the report[732](index=732&type=chunk) - A list of exhibits filed with the report is provided, including the **License Agreement with HanAll BioPharma**, the **Master Services Agreement with Samsung Biologics**, and various equity incentive plans[734](index=734&type=chunk)[735](index=735&type=chunk) [Form 10-K Summary](index=153&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company has not provided a summary for its Form 10-K - None[738](index=738&type=chunk)

[Corporate and Clinical Development Updates](index=1&type=section&id=Corporate%20and%20Clinical%20Development%20Updates) Immunovant strategically prioritizes IMVT-1402 for broad autoantibody-driven diseases, planning extensive late-stage clinical expansion and securing a key U.S. patent [General Clinical Development Updates](index=1&type=section&id=General%20Clinical%20Development%20Updates) Immunovant prioritizes IMVT-1402 for autoantibody-driven diseases, planning 4-5 registrational studies by March 2025 and securing a U.S. patent until 2043 - Immunovant is prioritizing the development of IMVT-1402 as its lead asset, citing its potential best-in-class features for treating a wide range of autoantibody-driven indications[4](index=4&type=chunk) - The company plans to initiate **4-5 potentially registrational programs** for IMVT-1402 by March 31, 2025, and expand to a total of **10 indications** by March 31, 2026, covering areas like Endocrinology and Neurology[5](index=5&type=chunk)[7](index=7&type=chunk) - A new U.S. Patent (No. 11,926,669) has been awarded for IMVT-1402, covering its composition of matter, with the patent term extending until **June 2043**[6](index=6&type=chunk) - Key data readouts are expected in the current fiscal year, including topline data for batoclimab in Myasthenia Gravis (MG) and detailed results for Graves' disease in the **fall of 2024**[7](index=7&type=chunk) [Neurology Clinical Development Updates](index=2&type=section&id=Neurology%20Clinical%20Development%20Updates) Immunovant plans a registrational program for IMVT-1402 in MG this fiscal year, while extending the batoclimab CIDP trial to optimize future IMVT-1402 studies - A potentially registrational program for IMVT-1402 in Myasthenia Gravis (MG) is expected to be initiated this fiscal year, with a final decision based on topline results from the current batoclimab trial, expected by **March 31, 2025**[8](index=8&type=chunk) - The company is extending the ongoing batoclimab CIDP trial by about **two quarters** before unblinding, aiming to use data from this trial and learnings from other CIDP studies to optimize the design of a future IMVT-1402 CIDP trial[9](index=9&type=chunk)[10](index=10&type=chunk) [Endocrinology Clinical Development Updates](index=2&type=section&id=Endocrinology%20Clinical%20Development%20Updates) Detailed batoclimab Graves' disease results and IMVT-1402 program overview are due in fall 2024, with a TED asset decision expected in early 2025 - Detailed results from the batoclimab study in Graves' disease and an overview of the IMVT-1402 development program are expected to be announced in the **fall of 2024**[11](index=11&type=chunk) - For Thyroid Eye Disease (TED), a decision on which asset (batoclimab or IMVT-1402) to advance to registration will be made in the **first half of calendar year 2025**, coinciding with the release of topline data from the current batoclimab TED program[12](index=12&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Immunovant reported increased net losses for both the fourth quarter and full fiscal year 2024, primarily driven by higher R&D expenses, while maintaining a strong cash position [Fourth Quarter Fiscal Year 2024 Financial Highlights](index=2&type=section&id=Financial%20Highlights%20for%20Fiscal%20Fourth%20Quarter%20Ended%20March%2031%2C%202024) Immunovant reported a **$75.3 million net loss** for Q4 FY2024, driven by increased R&D expenses, while maintaining a strong **$635 million cash position** - As of March 31, 2024, the company's cash and cash equivalents totaled approximately **$635 million**[13](index=13&type=chunk) Fourth Quarter Fiscal Year 2024 Financial Metrics | Financial Metric | Three Months Ended March 31, 2024 (Millions USD) | Three Months Ended March 31, 2023 (Millions USD) | | :--- | :--- | :--- | | R&D Expenses | $66.1 | $51.8 | | G&A Expenses | $14.8 | $12.4 | | Net Loss | $75.3 | $59.4 | | Net Loss per Share | $0.52 | $0.46 | [Fiscal Year 2024 Financial Highlights](index=3&type=section&id=Financial%20Highlights%20for%20Fiscal%20Year%20Ended%20March%2031%2C%202024) Immunovant's full fiscal year 2024 net loss widened to **$259.3 million**, primarily due to increased R&D and G&A expenses, alongside acquired in-process R&D costs Fiscal Year 2024 Financial Metrics | Financial Metric | Fiscal Year Ended March 31, 2024 (Millions USD) | Fiscal Year Ended March 31, 2023 (Millions USD) | | :--- | :--- | :--- | | R&D Expenses | $212.9 | $160.3 | | IPR&D Expenses | $12.5 | $10.0 | | G&A Expenses | $57.3 | $48.0 | | Net Loss | $259.3 | $211.0 | | Net Loss per Share | $1.88 | $1.71 | [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) Immunovant's consolidated financial statements reflect increased operating expenses and a widened net loss for fiscal year 2024, alongside a strengthened balance sheet with higher assets and equity [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Total operating expenses increased to **$282.7 million** in fiscal year 2024, leading to a net loss of **$259.3 million**, primarily due to higher R&D and G&A costs Consolidated Statements of Operations (Thousands USD) | (In thousands) | Year Ended March 31, 2024 | Year Ended March 31, 2023 | | :--- | :--- | :--- | | Research and development | $212,928 | $160,257 | | Acquired in-process R&D | $12,500 | $10,000 | | General and administrative | $57,281 | $48,019 | | **Total operating expenses** | **$282,709** | **$218,276** | | Interest income | ($24,948) | ($7,578) | | **Net loss** | **($259,336)** | **($210,960)** | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) Immunovant's total assets grew to **$666.4 million** by March 31, 2024, driven by increased cash and equivalents, resulting in a substantial rise in stockholders' equity Consolidated Balance Sheets (Thousands USD) | (In thousands) | March 31, 2024 | March 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $635,365 | $376,532 | | Total current assets | $665,770 | $404,333 | | **Total assets** | **$666,365** | **$405,838** | | **Liabilities and Equity** | | | | Total current liabilities | $48,608 | $43,297 | | **Total liabilities** | **$48,608** | **$43,344** | | **Total stockholders' equity** | **$617,757** | **$362,494** | | **Total liabilities and stockholders' equity** | **$666,365** | **$405,838** |

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024. "We are very excited about the immunology market evolution that we believe positions the anti-FcRn mechanism to be the leading therapeutic class across a broad range of autoantibody-driven indications. Within the ...

Core Insights - Immunovant, Inc. is focused on developing IMVT-1402 as a leading therapeutic asset in the immunology market, particularly for autoantibody-driven diseases [2][3] - The company plans to initiate multiple late-stage clinical programs for IMVT-1402 across various therapeutic areas, including endocrinology and neurology, with a goal of starting 4 to 5 registrational studies by March 31, 2025 [3][7] Clinical Development Updates - Immunovant is prioritizing IMVT-1402 for first-in-class indications such as Graves' disease and Myasthenia Gravis (MG), with plans to initiate studies in a total of 10 indications by March 31, 2026 [3][9] - The company has received a U.S. patent for IMVT-1402, which will extend until June 2043, covering its composition and methods of use [4] - The ongoing batoclimab trials are expected to inform the design of future registrational studies for IMVT-1402 in MG and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [5][6][8] Financial Highlights - As of March 31, 2024, Immunovant reported cash and cash equivalents of approximately $635 million [11] - Research and development expenses for the fourth quarter were $66.1 million, up from $51.8 million in the same period the previous year, primarily due to increased costs associated with IMVT-1402 [12] - The net loss for the fourth quarter was $75.3 million, compared to a net loss of $59.4 million in the prior year [14] - For the fiscal year ended March 31, 2024, total research and development expenses were $212.9 million, an increase from $160.3 million in the previous fiscal year [15]

Biohaven (BHVN) stock crashed Wednesday after the company's experimental protein-degrading drug — which could be used to treat a myriad of immune-related diseases — lagged investor expectations. X The company tested four doses of its drug, BHV-1300, which is meant to break down immunoglobulin G, or IgG, an autoantibody at the center of diseases like rheumatoid arthritis and myasthenia gravis. In healthy volunteers, the doses reduced IgG by up to 37%. Biohaven called the results "positive," noting that IgG l ...

Shares of Immunovant, Inc. (IMVT) have gained 0.1% over the past four weeks to close the last trading session at $29.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.56 indicates a potential upside of 68.6%. The average comprises 16 short-term price targets ranging from a low of $32 to a high of $57, with a standard deviation of $6.11. While the lowest estimate indicates ...

Immunovant, Inc. (IMVT) is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products in its commercial portfolio.Immunovant’s clinical-stage pipeline comprises its lead product candidate, batoclimab (formerly known as IMVT-1401), and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases.Let’s delve deeper to discuss ...

Investors might want to bet on Immunovant, Inc. (IMVT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inves ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-2771572 (State or other jurisdiction of incorporati ...